| 1 |
Katoh K, Kutsumura N, Yamamoto N, Nagumo Y, Saitoh T, Ishikawa Y, Irukayama-Tomobe Y, Tanimura R, Yanagisawa M, Nagase H. Essential structure of orexin 1 receptor antagonist YNT-707: Conversion of the 16-cyclopropylmethyl group to the 16-sulfonamide group in D-nor-nalfurafine derivatives. Bioorg Med Chem Lett 2022;:128550. [PMID: 35041942 DOI: 10.1016/j.bmcl.2022.128550] [Reference Citation Analysis]
|
| 2 |
Ohrui S, Yamamoto N, Saitoh T, Kutsumura N, Nagumo Y, Irukayama-tomobe Y, Ogawa Y, Ishikawa Y, Watanabe Y, Hayakawa D, Gouda H, Yanagisawa M, Nagase H. Essential structure of orexin 1 receptor antagonist YNT-707, Part II: Drastic effect of the 14-hydroxy group on the orexin 1 receptor antagonistic activity. Bioorganic & Medicinal Chemistry Letters 2018;28:774-7. [DOI: 10.1016/j.bmcl.2017.12.069] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
|
| 3 |
Saitoh T, Seki K, Nakajima R, Yamamoto N, Kutsumura N, Nagumo Y, Irukayama-Tomobe Y, Ogawa Y, Ishikawa Y, Tanimura R, Yanagisawa M, Nagase H. Essential structure of orexin 1 receptor antagonist YNT-707, Part IV: The role of D-ring in 4,5-epoxymorphinan on the orexin 1 receptor antagonistic activity. Bioorg Med Chem Lett 2019;29:2655-8. [PMID: 31375290 DOI: 10.1016/j.bmcl.2019.07.039] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 4 |
Watanabe H, Fukui K, Shimizu Y, Idoko Y, Nakamoto Y, Togashi K, Saji H, Ono M. Synthesis and biological evaluation of F-18 labeled tetrahydroisoquinoline derivatives targeting orexin 1 receptor. Bioorganic & Medicinal Chemistry Letters 2019;29:1620-3. [DOI: 10.1016/j.bmcl.2019.04.044] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 5 |
Sun Y, Tisdale RK, Kilduff TS. Hypocretin/Orexin Receptor Pharmacology and Sleep Phases. Front Neurol Neurosci 2021;45:22-37. [PMID: 34052813 DOI: 10.1159/000514963] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 6 |
Saitoh T, Seki K, Nakajima R, Yamamoto N, Kutsumura N, Nagumo Y, Irukayama-Tomobe Y, Ogawa Y, Ishikawa Y, Yanagisawa M, Nagase H. Essential structure of orexin 1 receptor antagonist YNT-707, part V: Structure-activity relationship study of the substituents on the 17-amino group. Bioorg Med Chem Lett 2020;30:126893. [PMID: 31879208 DOI: 10.1016/j.bmcl.2019.126893] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 7 |
Perrey DA, Zhang Y. Therapeutics development for addiction: Orexin-1 receptor antagonists. Brain Res 2020;1731:145922. [PMID: 30148984 DOI: 10.1016/j.brainres.2018.08.025] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 5.5] [Reference Citation Analysis]
|
